/PRNewswire/ miR Scientific, LLC announces the appointment of Erik Johnson, a seasoned leader in pharma and oncology, as Chief Operating Officer. This.
/PRNewswire/ miR Scientific, LLC announces the appointment of Erik Johnson, a seasoned leader in pharma and oncology, as Chief Operating Officer. This.
/PRNewswire/ miR Scientific, LLC, a healthcare company dedicated to transforming global cancer management by providing early and highly accurate detection,.
Errant Gene Therapeutics Becomes San Rocco Therapeutics
Errant Gene Therapeutics was founded in 1993, after founder Pat Girondi s son was diagnosed with Thalassemia, a cousin disease to Sickle Cell Anemia.
In 2007, with the help of researchers from Memorial Sloan Kettering, Cornell and National Institute of Health, EGT became the first entity to pass the FDA Recombinant DNA Committee for gene therapy in Sickle Cell Disease and Beta Thalassemia. EGT was the first company to get Orphan Drug Designation for Thalassemia in the US and Europe and first to produce a commercial batch (8-10 patients) of gene therapy for Sickle Cell Disease and Thalassemia. EGT is the company with the longest track record of treating US patients and the only company with experience in both harsh and soft chemotherapeutic prep-regimens.